Analyst Price Target is $8.67
▲ +386.89% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Quince Therapeutics in the last 3 months. The average price target is $8.67, with a high forecast of $11.00 and a low forecast of $6.00. The average price target represents a 386.89% upside from the last price of $1.78.
Current Consensus is
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Quince Therapeutics. This rating changed within the last month from a Strong Buy consensus rating.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More
